Related factors to atazanavir plasma levels in a cohort of HIV positive individuals with undetectable viral load

OBJECTIVE: To evaluate the factors associated with plasma concentrations of atazanavir (ATV) in a cohort of well-controlled HIV infected subjects (undetectable viremia). Design: Cross-sectional study where 69 subjects were consecutively enrolled between April and November, 2011. METHODS: Patients ha...

Full description

Bibliographic Details
Main Authors: Ana Júlia Luz, Júlia Poeta, Rafael Linden, Marina Venzon Antunes, Luiza Isola Caminha, Eduardo Sprinz
Format: Article
Language:English
Published: Elsevier
Series:Brazilian Journal of Infectious Diseases
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702013000600006&lng=en&tlng=en
id doaj-211e329d955147629f84288e55473d8b
record_format Article
spelling doaj-211e329d955147629f84288e55473d8b2020-11-25T02:49:53ZengElsevierBrazilian Journal of Infectious Diseases1678-439117665766010.1016/j.bjid.2013.04.002S1413-86702013000600006Related factors to atazanavir plasma levels in a cohort of HIV positive individuals with undetectable viral loadAna Júlia Luz0Júlia Poeta1Rafael Linden2Marina Venzon Antunes3Luiza Isola Caminha4Eduardo Sprinz5Universidade Federal do Rio Grande do SulUniversidade Federal do Rio Grande do SulUniversidade FEEVALEUniversidade FEEVALECentro Universitário Metodista do IPAUniversidade Federal do Rio Grande do SulOBJECTIVE: To evaluate the factors associated with plasma concentrations of atazanavir (ATV) in a cohort of well-controlled HIV infected subjects (undetectable viremia). Design: Cross-sectional study where 69 subjects were consecutively enrolled between April and November, 2011. METHODS: Patients had to be on atazanavir for at least six months, undetectable viral load for a period equal to or longer than 12 months, T CD4+ lymphocyte count higher than 200 cells/mm³, and aged between 18 years and 70 years old. Exclusion criteria were pregnancy, any neurologic disease, active opportunistic disease, hepatitis or cancer. Atazanavir plasma levels were measured by ultra-performance liquid chromatography. RESULTS AND DISCUSSION: Overall, 54 patients (mean age of 47 years and 50% women) were included in the analysis. Those without ritonavir (unboosted atazanavir) had statistically lower plasma concentrations than those with ritonavir boosted atazanavir (p = 0.001) and total and indirect bilirubin were statistically associated with plasma concentration of atazanavir (r = 0.32 and r = 0.33 respectively; p < 0.05 in both cases). no statistical association was found among gender, ethnicity, age, weight, body mass index (BMI), lipid profile, and the plasma concentration of atazanavir. CONCLUSION: in summary, as expected, concomitant ritonavir use was the only factor associated with atazanavir plasma levels. prospective studies with a larger sample size might help to observe an association of atazanavir concentrations to other characteristics such as body weight, since the p-value showed to be close to significance (p = 0.068).http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702013000600006&lng=en&tlng=enAtazanavirPlasma levelsDrug concentrationRitonavirLipid profile
collection DOAJ
language English
format Article
sources DOAJ
author Ana Júlia Luz
Júlia Poeta
Rafael Linden
Marina Venzon Antunes
Luiza Isola Caminha
Eduardo Sprinz
spellingShingle Ana Júlia Luz
Júlia Poeta
Rafael Linden
Marina Venzon Antunes
Luiza Isola Caminha
Eduardo Sprinz
Related factors to atazanavir plasma levels in a cohort of HIV positive individuals with undetectable viral load
Brazilian Journal of Infectious Diseases
Atazanavir
Plasma levels
Drug concentration
Ritonavir
Lipid profile
author_facet Ana Júlia Luz
Júlia Poeta
Rafael Linden
Marina Venzon Antunes
Luiza Isola Caminha
Eduardo Sprinz
author_sort Ana Júlia Luz
title Related factors to atazanavir plasma levels in a cohort of HIV positive individuals with undetectable viral load
title_short Related factors to atazanavir plasma levels in a cohort of HIV positive individuals with undetectable viral load
title_full Related factors to atazanavir plasma levels in a cohort of HIV positive individuals with undetectable viral load
title_fullStr Related factors to atazanavir plasma levels in a cohort of HIV positive individuals with undetectable viral load
title_full_unstemmed Related factors to atazanavir plasma levels in a cohort of HIV positive individuals with undetectable viral load
title_sort related factors to atazanavir plasma levels in a cohort of hiv positive individuals with undetectable viral load
publisher Elsevier
series Brazilian Journal of Infectious Diseases
issn 1678-4391
description OBJECTIVE: To evaluate the factors associated with plasma concentrations of atazanavir (ATV) in a cohort of well-controlled HIV infected subjects (undetectable viremia). Design: Cross-sectional study where 69 subjects were consecutively enrolled between April and November, 2011. METHODS: Patients had to be on atazanavir for at least six months, undetectable viral load for a period equal to or longer than 12 months, T CD4+ lymphocyte count higher than 200 cells/mm³, and aged between 18 years and 70 years old. Exclusion criteria were pregnancy, any neurologic disease, active opportunistic disease, hepatitis or cancer. Atazanavir plasma levels were measured by ultra-performance liquid chromatography. RESULTS AND DISCUSSION: Overall, 54 patients (mean age of 47 years and 50% women) were included in the analysis. Those without ritonavir (unboosted atazanavir) had statistically lower plasma concentrations than those with ritonavir boosted atazanavir (p = 0.001) and total and indirect bilirubin were statistically associated with plasma concentration of atazanavir (r = 0.32 and r = 0.33 respectively; p < 0.05 in both cases). no statistical association was found among gender, ethnicity, age, weight, body mass index (BMI), lipid profile, and the plasma concentration of atazanavir. CONCLUSION: in summary, as expected, concomitant ritonavir use was the only factor associated with atazanavir plasma levels. prospective studies with a larger sample size might help to observe an association of atazanavir concentrations to other characteristics such as body weight, since the p-value showed to be close to significance (p = 0.068).
topic Atazanavir
Plasma levels
Drug concentration
Ritonavir
Lipid profile
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702013000600006&lng=en&tlng=en
work_keys_str_mv AT anajulialuz relatedfactorstoatazanavirplasmalevelsinacohortofhivpositiveindividualswithundetectableviralload
AT juliapoeta relatedfactorstoatazanavirplasmalevelsinacohortofhivpositiveindividualswithundetectableviralload
AT rafaellinden relatedfactorstoatazanavirplasmalevelsinacohortofhivpositiveindividualswithundetectableviralload
AT marinavenzonantunes relatedfactorstoatazanavirplasmalevelsinacohortofhivpositiveindividualswithundetectableviralload
AT luizaisolacaminha relatedfactorstoatazanavirplasmalevelsinacohortofhivpositiveindividualswithundetectableviralload
AT eduardosprinz relatedfactorstoatazanavirplasmalevelsinacohortofhivpositiveindividualswithundetectableviralload
_version_ 1724741601938374656